Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

Participants in a new study who used GLP-1 drugs had a much lower cancer risk than those who had bariatric surgery.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

If a higher body weight is affecting your ability to get around, or you have joint pain from arthritis, it can impair your ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Lilly's obesity therapy recently outperformed Wegovy in a head-to-head weight loss study, while CagriSema's top-line efficacy was in the same ballpark as Zepbound in the phase 3 readout.